London: Antibodies against the Omicron variant of Kovid-19 have been reported to increase after the third booster dose of the AstraZeneca vaccinia vaccine. The Anglo-Swedish Biopharm Company said this in its preliminary data released on Thursday. An ongoing trial of the vaccine developed by Oxford University and being administered as Covishield in India has shown that its third dose increased the body’s immunity against beta, delta, alpha and gamma variants of SARS-CoV2.
‘The matter of rapid production of antibodies came to the fore’
A separate analysis of the test samples also revealed rapid antibody formation against the Omicron variant. Outcomes were studied in people who had received vaccinia or any mRNA vaccine. Sir M Pangolaj, Executive Vice President of Biopharmaceuticals R&D at AstraZeneca, said, “Vaxxaveria has saved millions of people worldwide from COVID-19 and these data show it has an important role as a third booster dose.” Even when it is given after other vaccines.
There are several million cases of Omicron variants in Europe
The company said that it is providing these additional data to health officials around the world in view of the urgent need for the third additional dose. The results of the Phase IV trial, published in a preprint with ‘The Lancet’, showed a rapid increase in antibodies from the third dose of Vaxjeveria after the initial vaccines for CoronaVac (Sinovac Biotech). The WHO recently said that in the first week of January, more than 7 million new cases of the Omicron variant of Kovid-19 were reported across Europe.